Gastrointestinal Cancer

Gastrointestinal Cancer Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Featured

Dr Shitara Talks Trastuzumab Deruxtecan for Treatment in HER2-Positive Gastric Cancer

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer, an approval based on results…

Dr Harris Highlights Multi-Platform Profiling With Biospecimens in Biliary Tract Cancer

William Harris, MD, discusses a feasibility study on using biospecimen-based multi-platform profiling for patients with resected biliary tract cancer.

Dr Diehl Talks NGS, ctDNA Monitoring, and Organoid Screening in Ongoing BTC Trial

Adam Diehl, MD, discusses an ongoing study assessing the ability to obtain NGS, ctDNA monitoring, and organoid drug sensitivity screening in patients with resected localized biliary tract cancer.

Dr King Highlights Progress of Ongoing Feasibility Study for Biliary Tract Cancer

Gentry King, MD, discusses an ongoing feasibility study on multiomic platform‑based testing in patients with localized and resectable biliary tract cancers.

Andres Cervantes, MD, PhD, Discusses Trastuzamab Deruxtecan as Emerging Therapy for Gastric Cancer

Dr Cervantes highlights the significance of the DESTINY-Gastric01 trial and discusses new advancements in the treatment of HER2+ gastric cancer.

Katrina Pedersen, MD, MS, Provides an Overview of Small Bowel Adenocarcinoma

Dr Pedersen discusses the history of small bowel adenocarcinoma, and phase 2 research informing the evolving treatment landscape for this disease.

Katrina Pedersen, MD, Discusses Findings of the RAPIDO Trial for Locally Advanced Rectal Cancer

Dr Pedersen talks about how short-course neoadjuvant chemotherapy improved outcomes over standard treatment in patients with locally advanced rectal cancer in the phase 3 RAPIDO trial.

Eileen O'Reilly, MD, on New Developments in Biliary Cancer Treatment

Eileen M O'Reilly, MD, highlights the treatment landscape of biliary cancer and new developments in 2020.

Gabriela Chiorean, MD, Discusses Takeaways from SWOG1505 Trial in Pancreatic Cancer

Dr Chiorean shares takeaways of the SWOG 1505 trial which did not determine perioperative modified FOLFIRINOX was superior to gemcitabine plus nab-paclitaxel in resectable pancreatic cancer.